Cuda Pharmaceuticals, LLC is a biotechnology and pharmaceutical company founded in 2013. The company's vision is to identify, develop and market a range of unique and limited access products across various markets including traditional generics, veterinary, OTC, NDA, and specialty/complex products. This approach aims to improve patient access to these products, thereby enhancing the lives of patients and expanding the choices for healthcare practitioners. In January 2019, Cuda Pharmaceuticals secured a Private Equity Round investment from Pleasant Bay Capital Partners. This investment demonstrates confidence in Cuda's potential to bring innovative and impactful products to the market. With a focus on addressing unmet medical needs, Cuda Pharmaceuticals is well-positioned to make significant contributions to the biotechnology and pharmaceutical industries. This recent investment reflects the recognition of Cuda's potential for growth and success in the healthcare sector.
No recent news or press coverage available for Cuda Pharmaceuticals, LLC.